This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, L.-C. Articles by Dahiya, R. Search for Related Content PubMed PubMed Citation Articles by Li, L.-C. Articles by Dahiya, R.

Frequent Methylation of Estrogen Receptor in Prostate Cancer: Correlation with Tumor Progression¹

Department of Urology, Veterans Affairs Medical Center, and University of California–San Francisco, San Francisco, California 94121

Prior studies have shown that the estrogen receptor (ER) gene is down-regulated in prostate cancer, but the mechanism of its inactivation is not known. We hypothesize that inactivation of the ER gene in prostate cancer is through promoter methylation. To test this hypothesis, we investigated the methylation status of the ER gene in prostate cancer cell lines, prostate cancer, and benign prostatic hyperplasia (BPH) tissues samples using the bisulfite genomic sequencing method. Our results show that the ER gene promoter was methylated in 100% (six of six) of the prostate cancer cell lines tested and all were accompanied by loss of ER mRNA expression. Treatment of these cell lines with demethylating agent 5-aza-2'-deoxycytidine restored ER mRNA expression in all of the ER-negative cell lines. In addition, elevated expression of DNA methyltransferase mRNA was found in all of the prostate cancer cell lines. Of the prostate tissue samples analyzed, 60% (6 of 10) in the BPH samples, 80% (8 of 10) in the low-grade cancer samples (grades I and II), and 95% (20 of 21) in the high-grade cancer samples (grades III-V) exhibited promoter methylation of the ER gene. The overall methylation levels in the cancer samples were higher than that in the BPH samples. The differences between the high-grade cancer samples and BPH samples were significant at all CpG sites. Only at three CpG sites were the differences significant between the low-grade cancer samples and BPH samples. This study presents the first evidence that ER gene is transcriptionally inactivated by DNA methylation in prostate cancer. Our data suggest that ER may be involved in the pathogenesis of prostate cancer, as well as BPH.

This article has been cited by other articles:

				H. Asada, Y. Yamagata, T. Taketani, A. Matsuoka, H. Tamura, N. Hattori, J. Ohgane, N. Hattori, K. Shiota, and N. Sugino Potential link between estrogen receptor-{alpha} gene hypomethylation and uterine fibroid formation Mol. Hum. Reprod., September 1, 2008; 14(9): 539 - 545. [Abstract] [Full Text] [PDF]

				J. C. Baker Jr., J. H. Ostrander, S. Lem, G. Broadwater, G. R. Bean, N. C. D'Amato, V. K. Goldenberg, C. Rowell, C. Ibarra-Drendall, T. Grant, et al. ESR1 Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1884 - 1890. [Abstract] [Full Text] [PDF]

				D. Y. Park, H. Sakamoto, S. D. Kirley, S. Ogino, T. Kawasaki, E. Kwon, M. Mino-Kenudson, G. Y. Lauwers, D. C. Chung, B. R. Rueda, et al. The Cables Gene on Chromosome 18q Is Silenced by Promoter Hypermethylation and Allelic Loss in Human Colorectal Cancer Am. J. Pathol., November 1, 2007; 171(5): 1509 - 1519. [Abstract] [Full Text] [PDF]

				Y.-F. Zhao, Y.-G. Zhang, X.-X. Tian, Juan Du, and Jie Zheng Aberrant Methylation of Multiple Genes in Gastric Carcinomas International Journal of Surgical Pathology, July 1, 2007; 15(3): 242 - 251. [Abstract] [PDF]

				L.-C. Li, S. T. Okino, H. Zhao, D. Pookot, R. F. Place, S. Urakami, H. Enokida, and R. Dahiya Small dsRNAs induce transcriptional activation in human cells PNAS, November 14, 2006; 103(46): 17337 - 17342. [Abstract] [Full Text] [PDF]

				A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]

				S.-M. Ho, W.-Y. Tang, J. Belmonte de Frausto, and G. S. Prins Developmental Exposure to Estradiol and Bisphenol A Increases Susceptibility to Prostate Carcinogenesis and Epigenetically Regulates Phosphodiesterase Type 4 Variant 4 Cancer Res., June 1, 2006; 66(11): 5624 - 5632. [Abstract] [Full Text] [PDF]

				L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]

				P. M. Das and R. Singal DNA Methylation and Cancer J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642. [Abstract] [Full Text] [PDF]

				J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF]

				M. Sasaki, M. Kaneuchi, N. Sakuragi, and R. Dahiya Multiple Promoters of Catechol-O-methyltransferase Gene Are Selectively Inactivated by CpG Hypermethylation in Endometrial Cancer Cancer Res., June 15, 2003; 63(12): 3101 - 3106. [Abstract] [Full Text] [PDF]

				M. Sasaki, Y. Tanaka, G. Perinchery, A. Dharia, I. Kotcherguina, S. i. Fujimoto, and R. Dahiya Methylation and Inactivation of Estrogen, Progesterone, and Androgen Receptors in Prostate Cancer J Natl Cancer Inst, March 6, 2002; 94(5): 384 - 390. [Abstract] [Full Text] [PDF]

				K. R Dimitrova, K. DeGroot, A. K Myers, and Y. D Kim Estrogen and homocysteine Cardiovasc Res, February 15, 2002; 53(3): 577 - 588. [Abstract] [Full Text] [PDF]

				J. F. Schmitt, D. S. Millar, J. S. Pedersen, S. L. Clark, D. J. Venter, M. Frydenberg, P. L. Molloy, and G. P. Risbridger Hypermethylation of the Inhibin {alpha}-Subunit Gene in Prostate Carcinoma Mol. Endocrinol., February 1, 2002; 16(2): 213 - 220. [Abstract] [Full Text] [PDF]

				D. Pasquali, V. Rossi, D. Esposito, C. Abbondanza, G. A. Puca, A. Bellastella, and A. A. Sinisi Loss of Estrogen Receptor {beta} Expression in Malignant Human Prostate Cells in Primary Cultures and in Prostate Cancer Tissues J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2051 - 2055. [Abstract] [Full Text]

				M. Sasaki, L. Kotcherguina, A. Dharia, S. Fujimoto, and R. Dahiya Cytosine-Phosphoguanine Methylation of Estrogen Receptors in Endometrial Cancer Cancer Res., April 1, 2001; 61(8): 3262 - 3266. [Abstract] [Full Text]

				A. Latil, I. Bièche, D. Vidaud, R. Lidereau, P. Berthon, O. Cussenot, and M. Vidaud Evaluation of Androgen, Estrogen (ER{{alpha}} and ER{beta}), and Progesterone Receptor Expression in Human Prostate Cancer by Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction Assays Cancer Res., March 1, 2001; 61(5): 1919 - 1926. [Abstract] [Full Text]

				M. Sasaki, A. Dharia, B. R. Oh, Y. Tanaka, S.-i. Fujimoto, and R. Dahiya Progesterone Receptor B Gene Inactivation and CpG Hypermethylation in Human Uterine Endometrial Cancer Cancer Res., January 1, 2001; 61(1): 97 - 102. [Abstract] [Full Text]

				C. I. Truica, S. Byers, and E. P. Gelmann {beta}-Catenin Affects Androgen Receptor Transcriptional Activity and Ligand Specificity Cancer Res., September 1, 2000; 60(17): 4709 - 4713. [Abstract] [Full Text]